Which embolic agent works best for brain bleeding? a trial aims to find out

NCT ID NCT07757113

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial compares three different embolic materials—particles, liquid embolics, and coils—used during a procedure called middle meningeal artery embolization to treat chronic subdural hematoma, a type of bleeding on the brain's surface. The study will enroll 30 adults undergoing this procedure and measure changes in hematoma size, complications, and recurrence rates. The goal is to see if one material is safer or more effective than the others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Embolic agents (particles, liquid embolics, or coils) used during middle meningeal artery embolization
What this could lead to
If successful, this could identify the best embolic material to reduce hematoma size and lower recurrence rates, improving outcomes for people with chronic subdural hematoma.
What could go wrong
This is a small pilot study, so results may not be definitive. The three materials may show similar outcomes, and individual risks like bleeding or complications vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SUBDURAL HEMATOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sanford USD Medical Center

    Sioux Falls, South Dakota, 57105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.